After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
AstraZeneca ended a tie-up with Asher, and then set off on its own.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
